Category

Archives

Blog of Signaling Pathways

Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study

392 views | Jul 19 2020

Paolo Bossi et al. showed a safety profile consistent with the whole population; older age did not affect safety or efficacy. [Read the Full Post]

4SC-202 induces apoptosis in myelodysplastic syndromes and the underlying mechanism

482 views | Jul 18 2020

Weili Wang et al. provided a novel therapeutic strategy for MDS. [Read the Full Post]

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors

0 views | Jul 18 2020

Xi Yuan et al. supported a vertical inhibition strategy in which RAF dimer and MEKi are combined to target K-RAS-mutated cancers. [Read the Full Post]

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial

584 views | Jul 17 2020

Andrew M Brunner et al. suggested that alisertib combined with induction chemotherapy is active and safe in previously untreated patients with high-risk acute myeloid leukaemia. [Read the Full Post]

In vitro and in vivo efficacies of inhibitors of the EGFR/MEK/ERK signaling in the treatment of alveolar echinococcosis

548 views | Jul 17 2020

Zhe Cheng et al. demonstrated the potential of EGFR-mediated signaling as a target for the development of novel anti-AE agents. [Read the Full Post]

A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model

213 views | Jul 16 2020

Lydia Bellmann found that combined BRAFi with an immune stimulating agent such as a TLR ligand could be a promising alternative approach for the treatment of melanoma. [Read the Full Post]

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

695 views | Jul 16 2020

Beata Holkova et al. showed a decrease in NF-κB activation and an increase in Bim levels in some patients, but these changes did not correlate with clinical response. [Read the Full Post]

A Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

968 views | Jul 15 2020

Yiqing Yang et al. found that PROTACs showed better selectivity and less adverse effects than inhibitors, indicating that PROTACs had a great potential for overcoming clinical drug resistance and safety issues. [Read the Full Post]

Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)

486 views | Jul 15 2020

Jason Kim et al. highlighted the potential use of two bioinformatics technologies to rapidly discover existing therapeutic agents that warranted further investigation for established and emerging disease processes. [Read the Full Post]

The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders

297 views | Jul 14 2020

Aude Robert et al. suggested that the use of agents targeting BCL-2, either alone or in combination with other conventional drugs, represented a novel promising approach for post-transplant EBV-positive B lymphoproliferative disorders. [Read the Full Post]

Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells

400 views | Jul 14 2020

Tamara Scheidt et al. provided evidence that phosphorylation triggered in response to SMO modulation dictated the localization of hedgehog pathway components within the primary cilium and affected the regulation of the SMO-SUFU-GLI axis. [Read the Full Post]

Protein Acetylation Derepresses Serotonin Synthesis to Potentiate Pancreatic Beta-Cell Function Through HDAC1-PKA-Tph1 Signaling

623 views | Jul 13 2020

Yuqing Zhang et al. highlighted a novel role of HDAC1-PKA-Tph1 signaling in governing β-cell functional compensation by derepressing serotonin synthesis. [Read the Full Post]

Lenvatinib and Sorafenib for Differentiated Thyroid Cancer After Radioactive Iodine: A Systematic Review and Economic Evaluation

555 views | Jul 13 2020

Nigel Fleeman et al.showed that compared with placebo/BSC, treatment with lenvatinib or sorafenib results in an improvement in PFS, objective tumour response rate and possibly OS, but dose modifications were required to treat AEs. [Read the Full Post]

SB203580 Protects Against Inflammatory Response and Lung Injury in a Mouse Model of lipopolysaccharide‑induced Acute Lung Injury

861 views | Jul 12 2020

Guirong Li et al. demonstrated that SB203580 protected against inflammatory responses and lung injury by inhibiting lung edema and downregulating proinflammatory mediators in LPS‑induced lung injury. [Read the Full Post]

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- And Benzamide-Type Histone Deacetylase Inhibitors (HDACi)

683 views | Jul 12 2020

Annabelle Friedrich et al. found that KSK64 revealed the highest genotoxic hazard and DDR stimulating potential, while TOK77 and MPK77 showed the lowest DNA damaging capacity. [Read the Full Post]

Copanlisib for the Treatment of Adults With Relapsed Follicular Lymphoma

248 views | Jul 09 2020

Massimo Magagnoli et al. found that teatment with copanlisib results in clinically relevant and durable responsed in heavily pretreated patients with relapsed or refractory FL. [Read the Full Post]

Inhibition of PI3K by Copanlisib Exerts Potent Antitumor Effects on Merkel Cell Carcinoma Cell Lines and Mouse Xenografts

236 views | Jul 09 2020

Bin Fang et al. provided compelling preclinical evidence for application of copanlisib in advanced MCC with aberrant PI3K activation for which immunotherapy was insufficient, or patients who were unsuitable for immunotherapy. [Read the Full Post]

The Dual PI3Kδ/CK1ε Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects on CLL T Cells

497 views | Jul 08 2020

Kamira Maharaj et al. suggested that the improved safety profile of umbralisib was due to its role as a dual PI3Kδ/CK1ε inhibitor that preserved Treg number and function. [Read the Full Post]

Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer

237 views | Jul 08 2020

Ivica Ratosa et al. observed a modest increase in the rates of grade 3 or higher AEs after combined RT and CDK4/6i, with maintained efficacy of concomitant RT. [Read the Full Post]

Histone Deacetylase Inhibition Prevents the Growth of Primary and Metastatic Osteosarcoma

917 views | Jul 07 2020

Jeremy J McGuire et al. provided rationale for clinical trials in osteosarcoma patients using the approved therapies panobinostat or romidepsin. [Read the Full Post]